HBV-resistance mutation profiles
| Baseline | At week 48 | At week 96 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistance mutations | Total | TDF-TDF | TDF/ETV-TDF | p Value* | Total | TDF-TDF | TDF/ETV-TDF | p Value* | Total | TDF-TDF | TDF/ETV-TDF | p Value* |
| N | 102 | 50 | 52 | – | 100 | 50 | 50 | – | 98 | 50 | 48 | – |
| Any HBV-resistance mutations, n (%) | 102 (100%) | 50 (100%) | 52 (100%) | >0.99 | 16 | 10 | 6 | 0.28 | 7 | 5 | 2 | 0.44 |
| Single resistance mutation to ADV (rtA181T/V or rtN236T), n (%) | 68 (66.7%) | 35 (70%) | 33 (63.5%) | 0.48 | 5 | 5 | 0 | 0.06 | 4 | 3 | 1 | 0.24 |
| rtN236T | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtN236T+rtM204V/I+rtL180M | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtN236T+rtM204V/I+rtL180M+rtM250L | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V | 7 | 3 | 4 | 4 | 4 | 0 | 2 | 2 | 0 | |||
| rtA181T/V+rtM204V/I | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtM204V/I+rtL180M | 27 | 16 | 11 | 1† | 0 | 1† | 1 | 1 | 0 | |||
| rtA181T/V+rtM204V/I+rtT184C/G/I | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtM204V/I+rtL180M+rtT184A/I/L | 7 | 1 | 6 | 2† | 0 | 2† | 0 | 0 | 0 | |||
| rtA181T/V+rtM204V/I+rtL180M+rtS202G | 8 | 4 | 4 | 3† | 1† | 2† | 1† | 1† | 0 | |||
| rtA181T/V+rtM204V+rtL180M+rtM250V | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtM204I+rtT184I+rtS202G | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtM204V+rtL180M+rtI169T+rtT184L | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtM204V/I+rtL180M+rtT184A/I/G/L+rtS202G | 5 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtM204V+rtL180M+rtT184A+rtM250V | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Double resistance mutation to ADV (rtA181T/V and rtN236T), n (%) | 34 (33.3%) | 15 (30%) | 19 (36.5%) | 0.48 | 5 | 4 | 1 | 0.15 | 2 | 1 | 1 | >0.99 |
| rtA181T/V+rtN236T | 7 | 5 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | |||
| rtA181T/V+rtN236T+rtM204V/I | 3 | 2 | 1 | 0 | 0 | 0 | 2‡ | 0 | 2‡ | |||
| rtA181T+rtN236T+rtL180M | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T+rtN236T+rtM250L | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 1 | 0 | |||
| rtA181T/V+rtN236T+rtM204V/I+rtL180M | 10 | 3 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtN236T+rtM204I+rtS202G | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtN236T+rtM204V/I+rtL180M+rtT184L | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T+rtN236T+rtM204V+rtL180M+rtS202G | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T+rtN236T+rtM204V/I+rtL180M+rtM250L | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtN236T+rtM204V/I+rtL180M+rtT184I/S+rtS202G | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtN236T+rtM204V/I+rtL180M+rtS202G+rtM250L | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtN236T+rtM204V/I+rtL180M+rtI169T+rtT184F+rtM250V | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T+rtN236T+rtM204V/I+rtL180M+rtT184I/L+rtS202G+rtM250L | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| rtA181T/V+rtN236T+rtM204V/I+rtL180M+rtI169T+rtT184IL+rtM250L | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |||
Resistance test was performed by both direct sequencing and RFMP analysis.
*Between the TDF-TDF and TDF/ETV-TDF groups.
†rtA181T/V mutation was not detected at week 48 and 96 in these patients.
‡Only rtM204I and rtA181V+rtM204I mutation, respectively, was detected at week 96 in each of these patients.
ADV, adefovir dipivoxil; ETV, entecavir; RFMP, restriction fragment mass polymorphism; TDF, tenofovir disoproxil fumarate.